Eli Lilly Reports Strong Q1 Performance with Revenue Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NVO?
Source: CNBC
- Significant Revenue Growth: Eli Lilly reported Q1 revenue of $19.8 billion, a 56% year-over-year increase that surpassed the market expectation of $17.6 billion, demonstrating strong performance in the obesity drug market and reinforcing investor confidence in the stock.
- Earnings Surge: Adjusted earnings per share reached $8.55, more than doubling from last year and exceeding the consensus estimate of $6.66, indicating the company's ability to achieve profitability despite declining drug prices.
- Competitive Market Dynamics: Despite competition from Novo Nordisk, CEO David Ricks emphasized that the company can overcome price declines through higher volumes, with U.S. drug prices down 7% but volumes up 49%, showcasing strong demand for its GLP-1 products.
- New Drug Launch and Market Outlook: The recently launched obesity drug Foundayo received FDA approval and became available quickly; although initial growth has been slow, 80% of prescriptions are from patients who had not previously used GLP-1 drugs, suggesting potential to expand the market size.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 40.290
Low
42.00
Averages
54.67
High
70.00
Current: 40.290
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Canada Approves Generic Semaglutide Injection by Dr. Reddy's
- Generic Approval: Health Canada approved a generic version of Novo Nordisk's GLP-1 drug semaglutide by Dr. Reddy's Laboratories, making Canada the first G7 country to do so, which is expected to enhance market competition and reduce patient costs.
- Indication Limitation: The approval is limited to the treatment of type 2 diabetes and does not include the weight loss indication for Wegovy, which may impact Dr. Reddy's potential revenue in the weight loss market, although the diabetes market remains substantial.
- Pending Applications: Health Canada noted that eight other applications for generic semaglutide are under review, including those from Teva Canada and Sandoz Canada, indicating strong market demand and competitive dynamics for this class of drugs.
- Market Outlook: With the introduction of generics, Novo Nordisk may face intensified competition, particularly within the GLP-1 duopoly, which could affect its future market share and profitability.
See More
Eli Lilly Reports Strong Q1 Performance with Revenue Surge
- Significant Revenue Growth: Eli Lilly reported Q1 revenue of $19.8 billion, a 56% year-over-year increase that surpassed the market expectation of $17.6 billion, demonstrating strong performance in the obesity drug market and reinforcing investor confidence in the stock.
- Earnings Surge: Adjusted earnings per share reached $8.55, more than doubling from last year and exceeding the consensus estimate of $6.66, indicating the company's ability to achieve profitability despite declining drug prices.
- Competitive Market Dynamics: Despite competition from Novo Nordisk, CEO David Ricks emphasized that the company can overcome price declines through higher volumes, with U.S. drug prices down 7% but volumes up 49%, showcasing strong demand for its GLP-1 products.
- New Drug Launch and Market Outlook: The recently launched obesity drug Foundayo received FDA approval and became available quickly; although initial growth has been slow, 80% of prescriptions are from patients who had not previously used GLP-1 drugs, suggesting potential to expand the market size.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
FDA Proposes Limiting Compounding of Obesity Drugs
- FDA Proposal Impact: The FDA's proposal to exclude the active ingredients of Novo Nordisk and Eli Lilly's obesity and diabetes medications from the compounding list could significantly limit the mass compounding of these drugs, potentially leading to higher costs for patients if finalized.
- Clinical Need Assessment: The FDA stated that there is 'no clinical need' for outsourcing facilities to compound these medications from bulk substances, emphasizing that when FDA-approved drugs are available, compounding is not lawful unless a clear clinical need exists, which may affect drug availability in the market.
- Market Response: Novo Nordisk and Eli Lilly have invested billions over recent years to ramp up manufacturing capacity to alleviate supply constraints, while also making efforts to enhance the affordability of their branded medications to attract users who previously opted for cheaper compounded alternatives.
- Regulatory Scope Clarification: The proposal specifically targets 503B outsourcing facilities that manufacture compounded drugs in bulk without prescriptions, while not affecting 503A pharmacies that compound based on individual prescriptions, indicating a tightening of FDA oversight in the compounding market.
See More
FDA Proposes Limiting Active Ingredients in Obesity Drugs
- Ingredient Exclusion Proposal: The FDA has proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's obesity and diabetes medications, which could limit mass compounding and affect market supply.
- Clinical Need Assessment: The FDA stated that when FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances without a clear clinical need, potentially impacting drug availability.
- Market Impact Analysis: This proposal specifically targets 503B outsourcing facilities, which may lead to a reduction in custom alternatives for drugs like Wegovy and Ozempic from Novo and Lilly, thus affecting patient choices and drug costs.
- Investment and Production Capacity: Novo and Lilly have invested billions over the past few years to ramp up manufacturing capacity to alleviate supply constraints while also striving to make their branded medications more competitive to attract users.
See More
FDA Proposes Restrictions on GLP-1 Compounding Drugs
- Positive Market Reaction: Following the FDA's proposal to restrict pharmacies from compounding GLP-1 drugs, shares of Eli Lilly and Novo Nordisk surged in early Thursday trading, reflecting investor confidence in their dominance in the weight loss drug market.
- Drug List Changes: The FDA's consideration to remove tirzepatide, semaglutide, and liraglutide from the 503B Bulk Drugs Substances List means pharmacies will no longer be able to compound these medications from bulk substances, potentially altering market supply dynamics.
- Clinical Need Assessment: The FDA noted that there is no clinical need for these three medications to remain on the list, which could help protect patients and maintain the integrity of the drug approval process, thereby impacting drug market availability and pricing strategies.
- Industry Outlook: With the FDA's proposal, the competitive landscape for Eli Lilly's Zepbound and Mounjaro, as well as Novo's Wegovy and Ozempic, may shift, prompting investors to monitor future market dynamics and company financial performance.
See More
Canada Approves Generic Semaglutide Injection by Dr. Reddy's
- Generic Approval: Health Canada approved a generic version of Novo Nordisk's GLP-1 drug semaglutide by Dr. Reddy's Laboratories, making Canada the first G7 country to do so, which is expected to enhance market competition and reduce patient costs.
- Indication Limitation: The approval is limited to the treatment of type 2 diabetes and does not include the weight loss indication for Wegovy, which may impact Dr. Reddy's potential revenue in the weight loss market, although the diabetes market remains substantial.
- Pending Applications: Health Canada noted that eight other applications for generic semaglutide are under review, including those from Teva Canada and Sandoz Canada, indicating strong market demand and competitive dynamics for this class of drugs.
- Market Outlook: With the introduction of generics, Novo Nordisk may face intensified competition, particularly within the GLP-1 duopoly, which could affect its future market share and profitability.
See More
Eli Lilly Reports Strong Q1 Performance with Revenue Surge
- Significant Revenue Growth: Eli Lilly reported Q1 revenue of $19.8 billion, a 56% year-over-year increase that surpassed the market expectation of $17.6 billion, demonstrating strong performance in the obesity drug market and reinforcing investor confidence in the stock.
- Earnings Surge: Adjusted earnings per share reached $8.55, more than doubling from last year and exceeding the consensus estimate of $6.66, indicating the company's ability to achieve profitability despite declining drug prices.
- Competitive Market Dynamics: Despite competition from Novo Nordisk, CEO David Ricks emphasized that the company can overcome price declines through higher volumes, with U.S. drug prices down 7% but volumes up 49%, showcasing strong demand for its GLP-1 products.
- New Drug Launch and Market Outlook: The recently launched obesity drug Foundayo received FDA approval and became available quickly; although initial growth has been slow, 80% of prescriptions are from patients who had not previously used GLP-1 drugs, suggesting potential to expand the market size.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
FDA Proposes Limiting Compounding of Obesity Drugs
- FDA Proposal Impact: The FDA's proposal to exclude the active ingredients of Novo Nordisk and Eli Lilly's obesity and diabetes medications from the compounding list could significantly limit the mass compounding of these drugs, potentially leading to higher costs for patients if finalized.
- Clinical Need Assessment: The FDA stated that there is 'no clinical need' for outsourcing facilities to compound these medications from bulk substances, emphasizing that when FDA-approved drugs are available, compounding is not lawful unless a clear clinical need exists, which may affect drug availability in the market.
- Market Response: Novo Nordisk and Eli Lilly have invested billions over recent years to ramp up manufacturing capacity to alleviate supply constraints, while also making efforts to enhance the affordability of their branded medications to attract users who previously opted for cheaper compounded alternatives.
- Regulatory Scope Clarification: The proposal specifically targets 503B outsourcing facilities that manufacture compounded drugs in bulk without prescriptions, while not affecting 503A pharmacies that compound based on individual prescriptions, indicating a tightening of FDA oversight in the compounding market.
See More
FDA Proposes Limiting Active Ingredients in Obesity Drugs
- Ingredient Exclusion Proposal: The FDA has proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's obesity and diabetes medications, which could limit mass compounding and affect market supply.
- Clinical Need Assessment: The FDA stated that when FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances without a clear clinical need, potentially impacting drug availability.
- Market Impact Analysis: This proposal specifically targets 503B outsourcing facilities, which may lead to a reduction in custom alternatives for drugs like Wegovy and Ozempic from Novo and Lilly, thus affecting patient choices and drug costs.
- Investment and Production Capacity: Novo and Lilly have invested billions over the past few years to ramp up manufacturing capacity to alleviate supply constraints while also striving to make their branded medications more competitive to attract users.
See More
FDA Proposes Restrictions on GLP-1 Compounding Drugs
- Positive Market Reaction: Following the FDA's proposal to restrict pharmacies from compounding GLP-1 drugs, shares of Eli Lilly and Novo Nordisk surged in early Thursday trading, reflecting investor confidence in their dominance in the weight loss drug market.
- Drug List Changes: The FDA's consideration to remove tirzepatide, semaglutide, and liraglutide from the 503B Bulk Drugs Substances List means pharmacies will no longer be able to compound these medications from bulk substances, potentially altering market supply dynamics.
- Clinical Need Assessment: The FDA noted that there is no clinical need for these three medications to remain on the list, which could help protect patients and maintain the integrity of the drug approval process, thereby impacting drug market availability and pricing strategies.
- Industry Outlook: With the FDA's proposal, the competitive landscape for Eli Lilly's Zepbound and Mounjaro, as well as Novo's Wegovy and Ozempic, may shift, prompting investors to monitor future market dynamics and company financial performance.
See More
